CureVac B.V.(CVAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CVAC CureVac B.V.

Market Closed 12-12 16:00:00 EST

5.05

-0.07

-1.37%

盘后5.05

+0.000.00%

18:48 EST

High5.16	Low5.05	Vol644.39K
Open5.12	D1 Closing5.12	Amplitude2.15%
Mkt Cap1.14B	Tradable Cap635.64M	Total Shares225.17M
T/O3.28M	T/O Rate0.51%	Tradable Shares125.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CVAC","market":"US","secType":"STK","nameCN":"CureVac B.V.","latestPrice":5.05,"timestamp":1765573200000,"preClose":5.12,"halted":0,"volume":644387,"hourTrading":{"tag":"盘后","latestPrice":5.05,"preClose":5.05,"latestTime":"18:48 EST","volume":54,"amount":278.2,"timestamp":1765583310665},"delay":0,"floatShares":125869472,"shares":225172749,"eps":0.936486,"marketStatus":"Market Closed","change":-0.07,"latestTime":"12-12 16:00:00 EST","open":5.12,"high":5.16,"low":5.05,"amount":3280518.3746,"amplitude":0.021484,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.936486,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1597377600000,"exchange":"NASDAQ","adjPreClose":5.12,"preHourTrading":{"tag":"盘前","latestPrice":5.1197,"preClose":5.12,"latestTime":"09:27 EST","volume":3231,"amount":16486.5732975,"timestamp":1765549668611},"postHourTrading":{"tag":"盘后","latestPrice":5.05,"preClose":5.05,"latestTime":"18:48 EST","volume":54,"amount":278.2,"timestamp":1765583310665},"volumeRatio":0.9272796290511566,"impliedVol":1.3475,"impliedVolPercentile":0.644},"requestUrl":"/m/hq/s/CVAC/tweets","defaultTab":"tweets","newsList":[{"id":"2588386044","title":"BioNTech Secures 81.7% of CureVac Shares in Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588386044","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588386044?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:01","pubTimestamp":1764770473,"startTime":"0","endTime":"0","summary":"BioNTech is proceeding with an offer to exchange American Depositary Shares  for shares of CureVac. The offer has commenced, and relevant documents including an exchange offer prospectus and related materials have been filed with the U.S. Securities and Exchange Commission. CureVac has also submitted a recommendation statement regarding the offer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLb9w6jL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","NDAQ","BK4535","IE00B64PRP62.GBP","BK4568","BK4112","BK4551","BK4585","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4548","LU2210149790.SGD","BNTX","CVAC","BK4588","IE00BGHQF748.EUR","LU2095319765.USD"],"gpt_icon":0},{"id":"2588741058","title":"Can New Board Leadership at CureVac (CVAC) Shift the Narrative After Recent Earnings Decline?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588741058","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588741058?lang=en_us&edition=fundamental","pubTime":"2025-12-01 12:28","pubTimestamp":1764563312,"startTime":"0","endTime":"0","summary":"CureVac N.V. recently held an Extraordinary General Meeting where shareholders approved the conditional appointment of Ramón Zapata Gomez as managing director, alongside Sierk Poetting, James Ryan, and Annemarie Hanekamp as supervisory directors.\nShortly before these board changes, CureVac reported sharply lower sales and net income for the third quarter and nine months ended September 30, 2025, compared to the previous year.\nWith earnings showing substantial declines, we will examine how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cvac/curevac/news/can-new-board-leadership-at-curevac-cvac-shift-the-narrative","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cvac/curevac/news/can-new-board-leadership-at-curevac-cvac-shift-the-narrative","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CVAC"],"gpt_icon":0},{"id":"2586625283","title":"BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2586625283","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586625283?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:45","pubTimestamp":1764161109,"startTime":"0","endTime":"0","summary":"Nov 26 (Reuters) - BIONTECH SE <22UAy.DE>::*ANNOUNCED APPROVAL OF MATTERS RELATING TO EXCHANGE OFFER ( \"OFFER\") FOR ALL OUTSTANDING SHARES OF CUREVAC N.V. (NASDAQ: CVAC, \"CUREVAC\") AT EXTRAORDINARY GE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nRSD4RM6k7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","BK4139","BK4535","BK4588","BK4568","BK4548","BK4585","BK4551","CVAC"],"gpt_icon":0},{"id":"2586254782","title":"BioNTech shares update on exchange offer for CureVac shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586254782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586254782?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:35","pubTimestamp":1764160532,"startTime":"0","endTime":"0","summary":"BioNTech (BNTX) announced the approval of matters relating to the exchange offer for all outstanding shares of CureVac (CVAC) at the extraordinary ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biontech-shares-update-on-exchange-offer-for-curevac-shares-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biontech-shares-update-on-exchange-offer-for-curevac-shares-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4548","BK4568","BNTX","BK4535","BK4551","CVAC","BK4585","BK4588"],"gpt_icon":0},{"id":"2586407772","title":"CureVac NV Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586407772","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586407772?lang=en_us&edition=fundamental","pubTime":"2025-11-26 07:48","pubTimestamp":1764114509,"startTime":"0","endTime":"0","summary":"CureVac NV held an Extraordinary General Meeting on November 25, 2025. Shareholders approved all proposals related to BioNTech SE's public exchange offer for all outstanding shares in CureVac. The meeting approved the legal merger of CureVac with CureVac Merger B.V., with new shares issued to shareholders. Approval was also given for the subsequent sale and transfer of all outstanding shares in CureVac SE to BioNTech SE and the cancellation of all outstanding class A shares in CureVac Merger B.V. Additionally, the conditional release of managing directors from liability for the exercise of their duties was approved.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6rtQkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC","BK4139","BK4548","BK4588","BK4535","BNTX","BK4585","BK4568","BK4551"],"gpt_icon":0},{"id":"2585980554","title":"Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2585980554","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585980554?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:47","pubTimestamp":1763995637,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/11/49030696/nasdaq-surges-350-points-enlivex-therapeutics-shares-spike-higher","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENLV","PCOM","MNQmain","TWNP","USAW.SI","BK4007","SQQQ","IVP","QID","BK4122","TQQQ","TSYW.SI","CLSDQ","CVAC","BK4139","INHD","BK4539","NVIW.SI","QLD","CLSD","PMN","BK4185","PSQ","BK4006","BK4548","BK4209","BK4551",".IXIC","NQmain","USJW.SI","LENZ"],"gpt_icon":1},{"id":"2585462271","title":"CureVac Q3 EPS $1.41 Beats $(0.17) Estimate, Sales $63.295M Beat $14.520M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462271","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462271?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:18","pubTimestamp":1763990295,"startTime":"0","endTime":"0","summary":"CureVac (NASDAQ:CVAC) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $(0.17) by 929.41 percent. This is a 687.5 percent increase over losses of $(0.24) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/49028468/curevac-q3-eps-1-41-beats-0-17-estimate-sales-63-295m-beat-14-520m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC","BK4551","BK4139","BK4548"],"gpt_icon":0},{"id":"2585746247","title":"Update: CureVac Q3 Earnings, Revenue Fall; German Regulators Clear BioNTech Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2585746247","media":"MT Newswires Live","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585746247?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:12","pubTimestamp":1763989961,"startTime":"0","endTime":"0","summary":"CureVac  reported Q3 earnings Monday of 1.21 euros  per diluted share, down from 1.50 euros a year earlier.Revenue for the quarter ended Sept. 30 was 54.1 million euros, down from 493.9 million euros a year earlier.Two analysts polled by FactSet expected 21.4 million euros.The decline in revenue was primarily driven by the absence of a one-time revenue of 480.4 million euros recognized in Q3 2024 in connection with the new license agreement with GlaxoSmithKline Biologicals.As of Sept. 30, the company said it had 416.1 million euros in cash and cash equivalents. It also reaffirmed its expected cash runway into 2028.CureVac said the German Federal Cartel Office has approved BioNTech's  planned acquisition of the company, a key step in completing the deal later this year.BioNTech's public exchange offer for all CureVac's shares will run until Dec. 3, the company said, adding that it has scheduled an extraordinary general meeting of shareholders on Tuesday in connection with the offer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","BK4568","BK4548","BK4588","BK4139","BNTX","BK4535","BK4585","CVAC"],"gpt_icon":0},{"id":"2585462699","title":"CureVac reports Q3 EPS EUR 1.21 vs. EUR 1.51 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462699","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462699?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:55","pubTimestamp":1763988943,"startTime":"0","endTime":"0","summary":"07:50 EST CureVac (CVAC) reports Q3 EPS EUR 1.21 vs. EUR 1.51 last year Published first on TheFly – the ultimate source for real-time, market-movin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/curevac-reports-q3-eps-eur-1-21-vs-eur-1-51-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/curevac-reports-q3-eps-eur-1-21-vs-eur-1-51-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4139","CVAC","BK4548"],"gpt_icon":0},{"id":"2585649264","title":"Earnings Flash (CVAC) CureVac Posts Q3 EPS 1.21 Euros","url":"https://stock-news.laohu8.com/highlight/detail?id=2585649264","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585649264?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:40","pubTimestamp":1763988055,"startTime":"0","endTime":"0","summary":"Earnings Flash (CVAC) CureVac Posts Q3 EPS 1.21 Euros","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CVAC"],"gpt_icon":0},{"id":"2585464827","title":"BioNTech Offer for CureVac Shares Enters Final Phase After Regulatory Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2585464827","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585464827?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:30","pubTimestamp":1763987443,"startTime":"0","endTime":"0","summary":"BioNTech's planned acquisition of CureVac took a step forward as the German Federal Cartel Office granted clearance for the transaction first announced in June 2025. The offer period for BioNTech's public exchange offer for all outstanding CureVac N.V. shares began on October 21, 2025, and is scheduled to close on December 3, 2025. An Extraordinary General Meeting of CureVac shareholders has been scheduled for November 25, 2025, as both companies aim to accelerate the development of innovative mRNA-based therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via ACCESS Newswire  on November 24, 2025, and is solely responsible for the information contained the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL4VJdNj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4548","BK4588","BK4139","BK4535","CVAC","BK4568","BNTX","BK4551"],"gpt_icon":0},{"id":"2585746103","title":"Curevac Reaffirms Its Expected Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2585746103","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585746103?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:23","pubTimestamp":1763987014,"startTime":"0","endTime":"0","summary":"Nov 24 (Reuters) - CUREVAC NV <5CV.DE>::*CUREVAC Q3 REVENUE EUR 54.1 MILLION VERSUS. IBES ESTIMATE EUR 3.34 MILLION*CUREVAC Q3 EBIT EUR 310.2 MILLION*CUREVAC NV - COMPANY REAFFIRMS ITS EXPECTED CASH R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nRSDbD80bt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4588","CVAC","BNTX","BK4139","BK4585","BK4551","BK4535","BK4568"],"gpt_icon":0},{"id":"2585461140","title":"CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461140","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461140?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:13","pubTimestamp":1763986402,"startTime":"0","endTime":"0","summary":"CureVac NV reported a net profit of 273.2 million for the third quarter of 2025, down from 338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was 161.6 million, compared to 194.9 million in the prior-year period. The net financial result showed a loss of 2.6 million for the third quarter of 2025, compared to a gain of 2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were 1.21, compared to 1.51 and 1.50 respectively in 2024. For the first nine months, basic earnings per share were 0.72 and diluted earnings per share were 0.71, down from 0.87 and 0.86 in the previous year. Revenues were 54.1 million for the third quarter and 56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstandi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL6dTwrC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4568","BK4139","BK4551","BK4548","BNTX","BK4535","CVAC"],"gpt_icon":0},{"id":"2585461192","title":"CureVac Nv - Company Reaffirms Its Expected Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461192?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:10","pubTimestamp":1763986247,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nPLX35A581:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4548","BK4551","CVAC"],"gpt_icon":0},{"id":"2585197461","title":"CureVac Nv - Net Financial Result for Three and Nine Months Ended September 30, 2025, Was Loss of EUR 2.6 Mln and Gain of EUR 2.2 Mln, Respectively","url":"https://stock-news.laohu8.com/highlight/detail?id=2585197461","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585197461?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:10","pubTimestamp":1763986247,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nPLX35A581:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4551","CVAC","BK4139"],"gpt_icon":0},{"id":"2585046119","title":"CureVac Nv - German Federal Cartel Office Clears BioNTech-CureVac Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2585046119","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585046119?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:10","pubTimestamp":1763986247,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nPLX35A581:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVAC","BK4551","BK4139","BK4548"],"gpt_icon":0},{"id":"2583547636","title":"Does CureVac’s 108% Rally Signal a Smarter Opportunity After mRNA Breakthrough News?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583547636","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583547636?lang=en_us&edition=fundamental","pubTime":"2025-11-16 03:17","pubTimestamp":1763234266,"startTime":"0","endTime":"0","summary":"Ever wondered whether CureVac's stock is a hidden gem or a value trap? You're not alone as many investors are taking a closer look after a wild ride.\nDespite a turbulent three-year stretch, CureVac shares are up an eye-popping 107.9% in the past year, with a year-to-date gain of 53% sparking new optimism and debate about its outlook.\nRecent attention around CureVac has centered on developments in its mRNA vaccine research as well as fresh updates on ongoing clinical trials. These...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cvac/curevac/news/does-curevacs-108-rally-signal-a-smarter-opportunity-after-m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cvac/curevac/news/does-curevacs-108-rally-signal-a-smarter-opportunity-after-m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4548","DCF","BK4551","CVAC"],"gpt_icon":0},{"id":"2577551938","title":"CureVac NV Announces Date for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577551938","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577551938?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:47","pubTimestamp":1761310031,"startTime":"0","endTime":"0","summary":"CureVac N.V. has scheduled an extraordinary general meeting to be held in Amsterdam, the Netherlands, on November 25, 2025. During the meeting, proposals will be presented regarding the explanation of the exchange offer by BioNTech SE for ordinary shares in the capital of the company, as well as the consummation of a post-offer reorganization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief on October 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL24vW93:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4535","BK4588","BNTX","BK4585","BK4551","CVAC","BK4568","BK4139"],"gpt_icon":0},{"id":"2577363815","title":"BioNTech Launches Public Exchange Offer for All CureVac Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2577363815","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577363815?lang=en_us&edition=fundamental","pubTime":"2025-10-22 18:45","pubTimestamp":1761129917,"startTime":"0","endTime":"0","summary":"BioNTech SE has launched a public exchange offer for all outstanding shares of CureVac N.V., following a purchase agreement between the two companies. The transaction aims to combine the strengths of both organizations in mRNA science, enhancing research, development, manufacturing, and commercialization capabilities in mRNA-based cancer immunotherapies. CureVac shareholders are set to receive approximately $5.46 in BioNTech American Depositary Shares for each CureVac share, subject to a collar. The collaboration is designed to accelerate the development of innovative mRNA-based cancer treatments, advancing BioNTech's oncology strategy and expanding its pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL6LLCVg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","CVAC","LU2095319765.USD","IE00BGHQF748.EUR","BK4588","BK4548","NDAQ","BNTX","BK4568","BK4535","BK4585","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2575292646","title":"BioNTech Receives Approval to Fully Acquire CureVac, Says German Antitrust Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=2575292646","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575292646?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:39","pubTimestamp":1760441956,"startTime":"0","endTime":"0","summary":"BioNTech will fully acquire its Dutch competitor CureVac through a share swap, according to an announcement from the German Federal Cartel Office. The regulator stated there are no significant overlaps between the companies' research pipelines, particularly in mRNA-based medicines, and does not expect any restriction of innovation competition from the deal. BioNTech currently markets its COVID-19 vaccine \"COMIRNATY\" in cooperation with Pfizer, while CureVac has no approved products on the market. The potential applications of mRNA technology extend beyond COVID-19 vaccines to include cancer therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via pressetex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL1pxZPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","LU0058720904.USD","LU1894683264.USD","SG9999001176.SGD","SG9999002224.SGD","LU0234572021.USD","LU1057294990.SGD","LU0225284248.USD","IE000M9KFDE8.USD","BK4534","BK4599","LU0225771236.USD","LU1894683348.USD","SG9999011175.SGD","BK4550","BK4585","CVAC","LU1066051498.USD","LU0321505439.SGD","BNTX","SG9999001176.USD","LU0306807586.USD","LU0321505868.SGD","IE00B19Z3581.USD","BK4568","BK4581","BK4007","SG9999002232.USD","LU0170899867.USD","LU0306806265.USD","LU0868494617.USD","LU0985481810.HKD","LU1023059063.AUD","LU1066053197.SGD","LU0289739699.SGD","LU1883839398.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","BK4533","IE00BLSP4239.USD","LU0122379950.USD","SG9999013999.USD","SGXZ57979304.SGD","SG9999003800.SGD","BK4548","BK4139","IE0002270589.USD","LU0456855351.SGD","BK4535"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.curevac.com","stockEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0543},{"period":"3month","weight":-0.0543},{"period":"6month","weight":-0.0934},{"period":"1year","weight":0.5781},{"period":"ytd","weight":0.4809}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.081893},{"month":2,"riseRate":0.2,"avgChangeRate":-0.099557},{"month":3,"riseRate":0.2,"avgChangeRate":-0.055603},{"month":4,"riseRate":0.6,"avgChangeRate":0.064149},{"month":5,"riseRate":0.8,"avgChangeRate":0.233107},{"month":6,"riseRate":0.4,"avgChangeRate":-0.089668},{"month":7,"riseRate":0.2,"avgChangeRate":-0.076476},{"month":8,"riseRate":0.2,"avgChangeRate":-0.023047},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.136579},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.099323},{"month":11,"riseRate":0.833333,"avgChangeRate":0.241614},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.133044}],"exchange":"NASDAQ","name":"CureVac B.V.","nameEN":"CureVac B.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CureVac B.V.(CVAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CureVac B.V.(CVAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CureVac B.V.,CVAC,CureVac B.V.股票,CureVac B.V.股票老虎,CureVac B.V.股票老虎国际,CureVac B.V.行情,CureVac B.V.股票行情,CureVac B.V.股价,CureVac B.V.股市,CureVac B.V.股票价格,CureVac B.V.股票交易,CureVac B.V.股票购买,CureVac B.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CureVac B.V.(CVAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CureVac B.V.(CVAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction